The study is focused on whether doxycycline may slow the progression of emphysema (a type of chronic obstructive pulmonary disease), in people with well-controlled HIV who are current or former smokers.
Dr. Leonard and colleagues found that rituximab (Rituxan) plus lenalidomide (Revlimid) elicited superior progression-free survival for patients with relapsed/refractory indolent non-Hodgkin’s lymphoma.
The new award into REasons for Geographic and Racial Differences in Stroke – Myocardial Infarction (REGARDS-MI) will support both scientific aims and early-stage investigator training, with a focus on structural racism.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the U.S.
Dr. Artis and team continue to illuminate the role of ILC2s, a family of white blood cells, with a new discovery published in Nature that has resolved an ongoing controversy.
Dr. Prigerson and her team will be piloting several interventions targeted to end-stage cancer patients and their caregivers to promote better communication and informed decision-making about care options.
As reported in Cell, these pain-sensing neurons protect against inflammation in the gut as well as the associated tissue damage, apparently by secreting a molecule called substance P.
The breakthrough research holds promise for developing diagnostic tests for the prediction of cancer progression and therapy.
IPF, which causes progressive scarring of the lungs due to chronic lung inflammation, is usually fatal because it tends to be diagnosed late in the process when treatments are less effective.
This award is the largest federal grant ever given to Weill Cornell Medicine and represents 20 years of continuous funding for the CTSC under Dr. Imperato-McGinley’s direction.